Mark Wan - Profile and Investment Details

Investor Profile

Mark Wan is a Venture Capital, Private Equity Firm based in Portola Valley, California, United States with a diverse investment portfolio that includes companies such as Tibion Bionic Technologies, Calistoga Pharmaceuticals, Visiogen, Stio®, Hemosphere, FloSports, Inova Labs, Opus Medical, Calibra Medical, NeuroBionics, iScience Interventional, Concert Pharmaceuticals, Voyage Medical, iScience Surgical, Sirtris Pharmaceuticals, Ocera TherapeuticsBenvenue Medical, Ascend Health, QuintEvents, SquareOne, Arete Therapeutics, Coalescent Surgical, Evalve, VenueNext, a Shift4 Company, Street League Skateboarding, Satiety, TriReme Medical, Arbor Surgical Technologies, APT Pharmaceuticals, Cameron Health, SmoothShapes, Nevro, Volley, Vascular Architects, Pegasus Biologics, Respicardia, The Center from Health Promotion, Free & Clear, Spiration, Momentous, Vitra Bioscience, LipoScience, Access Closure, Aspen MedTech, Radiant Medical, Freeletics, Allux Medical, Crux Biomedical, North American Scientific, NovaSys, Neuronetics, Tracksmith, Reliant Technologies, LipoSonix, NeuroVista, NBI Development, Threshold Pharmaceuticals, NOVASYS MEDICAL, Confluent Surgical, VisionCare Ophthalmic Technologies, AcuFocus, Ingenuity Systems, SpinalMotion, Concuity, Baxano, . Over time, Mark Wan has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Mark Wan is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Sports Events, E-commerce, Events Services, Sports, Wellness, Investment Management, Digital Media, Fitness Technology, Portfolio Management, Sports Tech, Education, Venture Fundraising, Technology, Software Development, Manufacturing, Biotechnology, Media Technology, Gaming, Digital Transformation, Consumer Internet, Digital Content, B2C, Early Stage IT, Live Streaming, Health Diagnostics, Digital Health, Online Platforms, Medical, Information Technology, B2B, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Mark Wan, as their portfolio suggests a familiarity and interest in this area.

Understanding Mark Wan’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.